Other indications (e.g. myeloproliferative diseases)
Follow-Up Treatment
A Phase 3, Randomized, Open-Label Study of Axatilimab
Versus BAT in Participants With Chronic
Graft-Versus-Host Disease After at Least 2 Prior Lines of
Systemic Therapie
A Phase 3, Randomized, Open-Label Study of Axatilimab
Versus BAT in Participants With Chronic
Graft-Versus-Host Disease After at Least 2 Prior Lines of
Systemic Therapie
